Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 1.352
Filter
1.
MMWR Morb Mortal Wkly Rep ; 73(39): 883-887, 2024 Oct 03.
Article in English | MEDLINE | ID: mdl-39361547

ABSTRACT

Ice machines can harbor water-related organisms, and the use of ice or tap water for clinical care activities has been associated with infections in health care settings. During 2021-2022, a total of 23 cases of infection by Burkholderia multivorans (sequence type ST659) were reported at two southern California hospitals and linked to contaminated ice and water from ice machines. In addition to these 23 cases, this report also includes 23 previously unreported cases of B. multivorans ST659 infections that occurred during 2020-2024: 13 at a northern California hospital, eight at a hospital in Colorado, and two additional cases at one of the southern California hospitals. The same brand of ice machine and brands of filters, descaling, and sanitizing products were used by all four hospitals; B. multivorans was isolated from samples collected from ice machines in two of the hospitals. Whole genome sequencing indicated that all clinical and ice machine isolates were highly genetically similar (0-14 single nucleotide variant differences across 81% of the selected reference genome). Recommendations from public health officials to halt the outbreak included avoiding ice and tap water during clinical care activities. An investigation is ongoing to determine possible sources of ice machine contamination. During outbreaks of water-related organisms in health care facilities, health care personnel should consider avoiding the use of tap water, including ice and water from ice machines, for patient care.


Subject(s)
Burkholderia Infections , Hospitals , Ice , Humans , California/epidemiology , Colorado/epidemiology , Hospitals/statistics & numerical data , Burkholderia Infections/epidemiology , Water Microbiology , Middle Aged , Adult , Female , Male , Aged , Cross Infection/epidemiology , Cross Infection/prevention & control , Disease Outbreaks , Burkholderia cepacia complex/isolation & purification , Young Adult , Adolescent , Patient Care , Aged, 80 and over , Child , Equipment Contamination
2.
Int J Infect Dis ; 147: 107201, 2024 Oct.
Article in English | MEDLINE | ID: mdl-39103011

ABSTRACT

Burkholderia cepacia complex (BCC) encompasses opportunistic pathogen with various clinical manifestations ranging from no symptoms to severe respiratory infections and septicemia. Central nervous system infections caused by BCC are rare. To the best of our knowledge, we present the first reported case of choroid plexitis caused by BCC after severe COVID-19. A 67-year-old woman who had been previously diagnosed with COVID-19 presented with a mild fever and headache. Gadolinium-enhanced T1-weighted brain magnetic resonance imaging showed contrast effects in the right choroid plexus and encapsulated abscess. Gram staining of cerebrospinal fluid revealed the presence of gram-negative rods. Broad-range polymerase chain reaction amplification of 16S ribosomal RNA from the cerebrospinal fluid, followed by sequence analysis, identified BCC; thus, choroid plexitis caused by BCC was diagnosed. After prolonged antimicrobial treatment with a multiantibiotic regimen, the patient recovered completely. This case highlights the importance of long-term therapy with a carefully selected multiantibiotic regimen to achieve complete recovery after BCC infection.


Subject(s)
Burkholderia Infections , Burkholderia cepacia complex , COVID-19 , SARS-CoV-2 , Humans , Female , COVID-19/complications , COVID-19/diagnosis , Aged , Burkholderia cepacia complex/isolation & purification , Burkholderia Infections/diagnosis , Burkholderia Infections/drug therapy , Anti-Bacterial Agents/therapeutic use , Choroid Plexus/microbiology , Choroid Plexus/pathology , Choroid Plexus/diagnostic imaging , Magnetic Resonance Imaging , Choroiditis/microbiology , Choroiditis/drug therapy , Choroiditis/diagnosis
3.
Diagn Microbiol Infect Dis ; 110(2): 116429, 2024 Oct.
Article in English | MEDLINE | ID: mdl-39116652

ABSTRACT

This report describes the characterization of Burkholderia cenocepacia isolates belonging to sequence type (ST)-250, detected in eight patients with cystic fibrosis (CF) in Switzerland. We retrospectively analyzed 18 isolates of B. cenocepacia ST-250 isolated between 2003 and 2015 by whole-genome sequencing and evaluated clinical and epidemiological data. Single nucleotide polymorphism analysis of the B.°cenocepacia ST-250 lineage showed that the isolates from all patients cluster tightly, suggesting that this cluster has a recent common ancestor. Epidemiological investigations showed that six out of eight patients acquired B.°cenocepacia ST-250 in the years 2001-2006, where participation in CF summer camps was common. Two patients were siblings. Genomic relatedness of the B. cenocepacia ST-250 isolates supported transmission by close contact, however, a common source or nosocomial routes cannot be excluded. With respect to the fatal outcome in six patients, our study shows the importance of infection control measurements in CF patients with B.°cenocepacia.


Subject(s)
Burkholderia Infections , Burkholderia cenocepacia , Cystic Fibrosis , Whole Genome Sequencing , Humans , Cystic Fibrosis/microbiology , Cystic Fibrosis/complications , Switzerland/epidemiology , Burkholderia Infections/microbiology , Burkholderia Infections/epidemiology , Burkholderia Infections/transmission , Burkholderia cenocepacia/genetics , Burkholderia cenocepacia/classification , Male , Retrospective Studies , Female , Child , Adolescent , Genome, Bacterial/genetics , Polymorphism, Single Nucleotide , Child, Preschool , Adult , Young Adult
4.
Front Cell Infect Microbiol ; 14: 1426773, 2024.
Article in English | MEDLINE | ID: mdl-39193503

ABSTRACT

Introduction: The Burkholderia cepacia complex encompasses a group of gram-negative opportunistic pathogens that cause chronic lung infections in people with cystic fibrosis. Distinct from other respiratory pathogens, Burkholderia causes a unique clinical disease in a subset of patients known as 'cepacia syndrome', fulminant pneumonia accompanied by bacteraemia and sepsis with a mortality rate of up to 75%. Due to the bacteraemia associated with this disease, the mechanisms that allow Burkholderia to resist the bactericidal effects of serum complement-depending killing are vital. Antibodies usually promote serum killing; however, we have described 'cloaking antibodies', specific for lipopolysaccharides that paradoxically protect serum-sensitive bacteria from complement-mediated lysis. Cloaking antibodies that protect Pseudomonas aeruginosa have been found in 24%-41% of patients with chronic lung diseases. The presence of these antibodies is also associated with worse clinical outcomes. Here, we sought to determine the relevance of cloaking antibodies in patients with Burkholderia infection. Methods: Twelve Burkholderia spp. were isolated from nine pwCF and characterised for susceptibility to healthy control serum. Patient serum was analysed for the titre of the cloaking antibody. The ability of the patient serum to prevent healthy control serum (HCS) killing of its cognate isolates was determined. Results: We found that several of the Burkholderia strains were shared between patients. Ten of the 12 isolates were highly susceptible to HCS killing. Four of nine (44%) patients had cloaking antibodies that protected their cognate strain from serum killing. Depleting cloaking antibodies from patient serum restored HCS killing of Burkholderia isolates. Discussion: Cloaking antibodies are prevalent in patients with Burkholderia pulmonary infection and protect these strains from serum killing. Removal of cloaking antibodies via plasmapheresis, as previously described for individuals with life-threatening Pseudomonas infection, may be a useful new strategy for those with serious and life-threatening Burkholderia infection.


Subject(s)
Antibodies, Bacterial , Burkholderia Infections , Burkholderia cepacia complex , Humans , Burkholderia Infections/immunology , Burkholderia Infections/microbiology , Antibodies, Bacterial/blood , Burkholderia cepacia complex/immunology , Cystic Fibrosis/complications , Cystic Fibrosis/immunology , Cystic Fibrosis/microbiology , Female , Male , Adult , Lipopolysaccharides/immunology , Blood Bactericidal Activity , Middle Aged , Bacteremia/microbiology , Bacteremia/immunology
5.
J Microbiol Biotechnol ; 34(8): 1609-1616, 2024 Aug 28.
Article in English | MEDLINE | ID: mdl-39049470

ABSTRACT

The Burkholderia cepacia complex (Bcc) consists of opportunistic pathogens known to cause pneumonia in immunocompromised individuals, especially those with cystic fibrosis. Treating Bcc pneumonia is challenging due to the pathogens' high multidrug resistance. Therefore, inhalation therapy with tobramycin powder, which can achieve high antibiotic concentrations in the lungs, is a promising treatment option. In this study, we investigated potential mechanisms that could compromise the effectiveness of tobramycin therapy. By selecting for B. cenocepacia survivors against tobramycin, we identified three spontaneous mutations that disrupt a gene encoding a key enzyme in the biosynthesis of cobalamin (Vitamin B12). This disruption may affect the production of succinyl-CoA by methylmalonyl-CoA mutase, which requires adenosylcobalamin as a cofactor. The depletion of cellular succinyl-CoA may impact the tricarboxylic acid (TCA) cycle, which becomes metabolically overloaded upon exposure to tobramycin. Consequently, the mutants exhibited significantly reduced reactive oxygen species (ROS) production. Both the wild-type and mutants showed tolerance to tobramycin and various other bactericidal antibiotics under microaerobic conditions. This suggests that compromised ROS-mediated killing, due to the impacted TCA cycle, underlies the mutants' tolerance to bactericidal antibiotics. The importance of ROS-mediated killing and the potential emergence of mutants that evade it through the depletion of cobalamin (Vitamin B12) provide valuable insights for developing strategies to enhance antibiotic treatments of Bcc pneumonia.


Subject(s)
Anti-Bacterial Agents , Burkholderia cenocepacia , Mutation , Reactive Oxygen Species , Tobramycin , Vitamin B 12 , Vitamin B 12/pharmacology , Vitamin B 12/metabolism , Anti-Bacterial Agents/pharmacology , Burkholderia cenocepacia/drug effects , Burkholderia cenocepacia/genetics , Burkholderia cenocepacia/metabolism , Tobramycin/pharmacology , Reactive Oxygen Species/metabolism , Acyl Coenzyme A/metabolism , Microbial Sensitivity Tests , Drug Resistance, Bacterial/genetics , Citric Acid Cycle/drug effects , Humans , Methylmalonyl-CoA Mutase/genetics , Methylmalonyl-CoA Mutase/metabolism , Burkholderia Infections/microbiology , Burkholderia Infections/drug therapy , Bacterial Proteins/genetics , Bacterial Proteins/metabolism
6.
Front Cell Infect Microbiol ; 14: 1374318, 2024.
Article in English | MEDLINE | ID: mdl-39011515

ABSTRACT

Background: In current literature there are only scarce data on the host inflammatory response during Burkholderia cepacia complex (Bcc) persistence. The primary objective of the present research was to carry out cross-sectional analyses of biomarkers and evaluate disease progression in cystic fibrosis (CF) patients with chronic Bcc infection and pathogen-free ones. The secondary aim was to assess prospectively overall survival of the study participants during up to 8 years of follow-up. Methods: The study included 116 paediatric patients with CF; 47 CF patients were chronically infected with Bcc, and 69 individuals were Bcc free. Plasma and sputum biomarkers (neutrophil elastase, MMP-8, MMP-9, MMP-12, IL-2, IL-4, IL-6, IL-8, IL-10, IL-18, IL-22, IL-23, IL-17, IFN-γ, TGFß1, TNF-α) were analysed using commercially available kits. Besides, inhibitory effect of dexamethasone on proliferative response of PHA-stimulated peripheral blood lymphocytes had been assessed. Results: Bcc infected patients did not differ from Bcc free ones in demographic and clinical parameters, but demonstrated an increased rate of glucose metabolism disturbances and survival disadvantage during prolong follow-up period. Biomarkers analyses revealed elevated TNF-α and reduced IL-17F levels in sputum samples of Bcc infected patients. These patients also demonstrated improvement of peripheral blood lymphocyte sensitivity to steroid treatment and reduction in plasma pro-inflammatory (IL-17F and IL-18) and anti-inflammatory (TGFß1 and IL-10) cytokine concentrations. Conclusions: Reduction in IL-17F levels may have several important consequences including increase in steroid sensitivity and glycemic control disturbances. Further investigations are needed to clarify the role of IL-17 cytokines in CF complication development. Low plasma TGFß1 and IL-10 levels in Bcc infected group may be a sign of subverted activity of regulatory T cells. Such immune alterations may be one of the factors contributing to the development of the cepacia syndrome.


Subject(s)
Biomarkers , Burkholderia Infections , Cystic Fibrosis , Cytokines , Humans , Cystic Fibrosis/complications , Cystic Fibrosis/microbiology , Cystic Fibrosis/mortality , Child , Male , Female , Adolescent , Biomarkers/blood , Burkholderia Infections/mortality , Burkholderia Infections/immunology , Cross-Sectional Studies , Cytokines/blood , Cytokines/metabolism , Sputum/microbiology , Child, Preschool , Prospective Studies , Disease Progression , Burkholderia cepacia , Burkholderia cepacia complex
7.
Indian J Med Microbiol ; 50: 100655, 2024.
Article in English | MEDLINE | ID: mdl-38914312

ABSTRACT

Nosocomial outbreaks of Burkholderia cepacia complex, transmitted through contaminated medical surfaces or equipment have been reported. Pulsed-field Gel Electrophoresis (PFGE) is recognized as the "gold standard" for molecular subtyping, yet studies on clonal relationships in India are limited. PFGE was used to study the clonal relationships of 22 isolates of Burkholderia cenocepacia from 12 patients admitted to a critical care unit during 2 months (November and December 2021). PFGE revealed three different profiles with 15 isolates belonging to a single cluster suggesting a common source within the hospital, emphasizing the need for preventive measures to control B. cenocepacia transmission.


Subject(s)
Burkholderia Infections , Burkholderia cenocepacia , Cross Infection , Disease Outbreaks , Electrophoresis, Gel, Pulsed-Field , Intensive Care Units , Tertiary Care Centers , Humans , Burkholderia Infections/epidemiology , Burkholderia Infections/microbiology , Burkholderia cenocepacia/genetics , Burkholderia cenocepacia/classification , Burkholderia cenocepacia/isolation & purification , Cross Infection/epidemiology , Cross Infection/microbiology , India/epidemiology , Male , Female , Middle Aged , Adult , Molecular Typing/methods
8.
Br J Biomed Sci ; 81: 12749, 2024.
Article in English | MEDLINE | ID: mdl-38895586

ABSTRACT

Within cystic fibrosis microbiology, there is often mismatch between the antibiotic susceptibility result of an isolated bacterial pathogen and the clinical outcome, when the patient is treated with the same antibiotic. The reasoning for this remains largely elusive. Antibiotic susceptibility to four antibiotics (ceftazidime, meropenem, minocycline and trimethoprim-sulfamethoxazole) was determined in consecutive isolates (n = 11) from an adult cystic fibrosis patient, over a 63 month period. Each isolate displayed its own unique resistotype. The first isolate was sensitive to all four antibiotics, in accordance with Clinical and Laboratory Standards Institute methodology and interpretative criteria. Resistance was first detected at four months, showing resistance to ceftazidime and meropenen and intermediate resistance to minocycline and trimethoprim-sulfamethoxazole. Pan resistance was first detected at 18 months (resistotype IV), with three resistotypes (I, II and III) preceding this complete resistotype. The bacterium continued to display further antibiotic susceptibility heterogeneity for the next 45 months, with the description of an additional seven resistotypes (resistotypes V-XI). The Relative Resistance Index of this bacterium over the 63 month period showed no relationship between the development of antibiotic resistance and time. Adoption of mathematical modelling employing multinomial distribution demonstrated that large numbers of individual colony picks (>40/sputum), would be required to be 78% confident of capturing all 11 resistotypes present. Such a requirement for large numbers of colony picks combined with antibiotic susceptibility-related methodological problems creates a conundrum in biomedical science practice, in providing a robust assay that will capture antibiotic susceptibility variation, be pragmatic and cost-effective to deliver as a pathology service, but have the reliability to help clinicians select appropriate antibiotics for their patients. This study represents an advance in biomedical science as it demonstrates potential variability in antibiotic susceptibility testing with Burkholderia cenocepacia. Respiratory physicians and paediatricians need to be made aware of such variation by biomedical scientists at the bench, so that clinicians can contextualise the significance of the reported susceptibility result, when selecting appropriate antibiotics for their cystic fibrosis patient. Furthermore, consideration needs to be given in providing additional guidance on the laboratory report to highlight this heterogeneity to emphasise the potential for misalignment between susceptibility result and clinical outcome.


Subject(s)
Anti-Bacterial Agents , Burkholderia Infections , Burkholderia cenocepacia , Cystic Fibrosis , Microbial Sensitivity Tests , Cystic Fibrosis/microbiology , Cystic Fibrosis/drug therapy , Cystic Fibrosis/complications , Humans , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/pharmacology , Burkholderia cenocepacia/drug effects , Burkholderia cenocepacia/genetics , Burkholderia Infections/drug therapy , Burkholderia Infections/microbiology , Adult , Drug Resistance, Bacterial
9.
Clin Nucl Med ; 49(8): e421-e422, 2024 Aug 01.
Article in English | MEDLINE | ID: mdl-38861417

ABSTRACT

ABSTRACT: Nosocomial Burkholderia cepacia infection in the clinical setting of postrenal transplantation pyrexia of unknown origin and the role of 18 F-FDG PET/CT in treatment optimization in such situation is presented in this report. The consequence of fastidious infection by nosocomial colonizing organisms like B. cepacia can be catastrophic in immunocompromised postrenal transplant individuals causing severe urinary tract infection. In the presented case, following 2 weeks of IV antibiotics, the patient didn't show clinical response, and FDG PET scan recognized multifocal infective sites early, likely representing immune reconstitution inflammatory syndrome and timely appropriate and optimal treatment salvaged the renal graft.


Subject(s)
Burkholderia Infections , Burkholderia cepacia , Fluorodeoxyglucose F18 , Kidney Transplantation , Positron Emission Tomography Computed Tomography , Humans , Kidney Transplantation/adverse effects , Burkholderia Infections/diagnostic imaging , Burkholderia Infections/drug therapy , Male , Fever/etiology , Tomography, X-Ray Computed , Multimodal Imaging , Middle Aged
10.
Am J Trop Med Hyg ; 111(2): 281-286, 2024 Aug 07.
Article in English | MEDLINE | ID: mdl-38917784

ABSTRACT

Burkholderia spp. are opportunistic pathogens that cause infection in patients with disrupted immunity. The study intended to demonstrate the epidemiology and clinical features associated with Burkholderia spp. bacteremia. This retrospective study was performed to assess the clinical and laboratory characteristics of patients whose blood cultures were growing Burkholderia spp. and, based on their underlying comorbidities, were subjected to survival analysis from January 2022 to December 2022 at a university hospital in northern India. Three hundred patients with Burkholderia spp. bacteremia were included in this study conducted over 1 year. The mean age of the patients was 33.86 years with a male predominance of 56.67% (170/300, 56.67%). Underlying malignancies (207/300, 69.0%) were the most common clinical diagnosis, and catheter in situ (300/300, 100.0%) was the most common risk factor. Burkholderia cenocepacia (244/300, 81.33%) was the most common Burkholderia spp. isolated. All isolates were highly susceptible to minocycline. Kidney disease (P = 0.029), hypertension (P = 0.005), type 2 diabetes mellitus (P = 0.039), and respiratory disease (P <0.001) in patients were significantly associated with death owing to Burkholderia spp. bacteremia, whereas patients with malignancies (P <0.001) and undergoing treatment were significantly associated with a better outcome when the microorganism was susceptible to empirical antibiotics. The presence of indwelling devices, mechanical ventilation (P <0.001), and a hemodialysis catheter (P = 0.026) were statistically significant risk factors associated with poor outcomes.


Subject(s)
Bacteremia , Burkholderia Infections , Burkholderia , Humans , India/epidemiology , Male , Female , Bacteremia/epidemiology , Bacteremia/microbiology , Burkholderia Infections/epidemiology , Burkholderia Infections/microbiology , Adult , Retrospective Studies , Burkholderia/isolation & purification , Middle Aged , Young Adult , Risk Factors , Adolescent , Anti-Bacterial Agents/therapeutic use , Child , Aged , Neoplasms/complications , Neoplasms/epidemiology
12.
Eur J Clin Microbiol Infect Dis ; 43(7): 1349-1353, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38780755

ABSTRACT

INTRODUCTION: Burkholderia cepacia complex (BCC) are non-fermenting Gram-negative bacteria that can chronically colonize the lungs of people with cystic fibrosis (pwCF), causing a severe and progressive respiratory failure, post-transplant complications and epidemic outbreaks. Therefore, rapid and accurate identification of these bacteria is relevant for pwCF, in order to facilitate early eradication and prevent chronic colonization. However, BCCs are often quite difficult to detect on culture media as they have a slow growth rate and can be hidden by other fast-growing microorganisms, including Pseudomonas aeruginosa and filamentous fungi. MATERIAL AND METHODS: We evaluated the sensitivity of CHROMagar™ B. cepacia agar using 11 isolates from a well-characterized BCC collection, using BCA agar (Oxoid, UK) as a gold standard. We also studied 180 clinical sputum samples to calculate positive (PPV) and negative (NPV) predictive values. Furthermore, we used three of the well-characterized BCC isolates to determine the limit of detection (LOD). RESULTS: Eleven isolates grew on CHROMagar™ B. cepacia at 37ºC after 48 h. The NPV and PPV of CHROMagar™ B. cepacia were 100% and 87.5%, respectively. The LOD of CHROMagar™ B. cepacia was around 1 × 103 CFU/ml, requiring a ten-fold dilution lower bacterial load than BCA for BCC detection. CONCLUSION: CHROMagar™ B. cepacia agar proved to have a very good sensitivity and specificity for the detection of clinical BCCs. Moreover, the chromogenic nature of the medium allowed us to clearly differentiate BCC from other Gram-negative species, filamentous fungi and yeasts, thereby facilitating the identification of contaminants.


Subject(s)
Agar , Bacteriological Techniques , Burkholderia Infections , Burkholderia cepacia complex , Culture Media , Cystic Fibrosis , Sensitivity and Specificity , Sputum , Humans , Cystic Fibrosis/microbiology , Cystic Fibrosis/complications , Burkholderia cepacia complex/isolation & purification , Burkholderia cepacia complex/classification , Sputum/microbiology , Burkholderia Infections/microbiology , Burkholderia Infections/diagnosis , Culture Media/chemistry , Bacteriological Techniques/methods
13.
Microbiol Spectr ; 12(7): e0041024, 2024 Jul 02.
Article in English | MEDLINE | ID: mdl-38809005

ABSTRACT

The Burkholderia cepacia complex (Bcc) is a group of Gram-negative opportunistic bacteria often associated with fatal pulmonary infections in patients with impaired immunity, particularly those with cystic fibrosis (CF) and chronic granulomatous disease (CGD). Some Bcc strains are known to naturally produce pyomelanin, a brown melanin-like pigment known for scavenging free radicals; pigment production has been reported to enable Bcc strains to overcome the host cell oxidative burst. In this work, we investigated the role of pyomelanin in resistance to oxidative stress and virulence in strains J2315 and K56-2, two epidemic CF isolates belonging to the Burkholderia cenocepacia ET-12 lineage. We previously reported that a single amino acid change from glycine to arginine at residue 378 in homogentisate 1,2-dioxygenase (HmgA) affects the pigment production phenotype: pigmented J2315 has an arginine at position 378, while non-pigmented K56-2 has a glycine at this position. Herein, we performed allelic exchange to generate isogenic non-pigmented and pigmented strains of J2315 and K56-2, respectively, and tested these to determine whether pyomelanin contributes to the protection against oxidative stress in vitro as well as in a respiratory infection in CGD mice in vivo. Our results indicate that the altered pigment phenotype does not significantly impact these strains' ability to resist oxidative stress with H2O2 and NO in vitro and did not change the virulence and infection outcome in CGD mice in vivo suggesting that other factors besides pyomelanin are contributing to the pathophysiology of these strains.IMPORTANCEThe Burkholderia cepacia complex (Bcc) is a group of Gram-negative opportunistic bacteria that are often associated with fatal pulmonary infections in patients with impaired immunity, particularly those with cystic fibrosis and chronic granulomatous disease (CGD). Some Bcc strains are known to naturally produce pyomelanin, a brown melanin-like pigment known for scavenging free radicals and overcoming the host cell oxidative burst. We investigated the role of pyomelanin in Burkholderia cenocepacia strains J2315 (pigmented) and K56-2 (non-pigmented) and performed allelic exchange to generate isogenic non-pigmented and pigmented strains, respectively. Our results indicate that the altered pigment phenotype does not significantly impact these strains' ability to resist H2O2 or NO in vitro and did not alter the outcome of a respiratory infection in CGD mice in vivo. These results suggest that pyomelanin may not always constitute a virulence factor and suggest that other features are contributing to the pathophysiology of these strains.


Subject(s)
Burkholderia Infections , Burkholderia cenocepacia , Granulomatous Disease, Chronic , Homogentisate 1,2-Dioxygenase , Melanins , Animals , Female , Humans , Mice , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Burkholderia cenocepacia/genetics , Burkholderia cenocepacia/pathogenicity , Burkholderia cenocepacia/metabolism , Burkholderia Infections/microbiology , Cystic Fibrosis/microbiology , Disease Models, Animal , Granulomatous Disease, Chronic/microbiology , Granulomatous Disease, Chronic/genetics , Homogentisate 1,2-Dioxygenase/genetics , Homogentisate 1,2-Dioxygenase/metabolism , Lung/microbiology , Lung/pathology , Melanins/metabolism , Mutation , Oxidative Stress , Virulence/genetics
14.
Indian J Med Microbiol ; 49: 100613, 2024.
Article in English | MEDLINE | ID: mdl-38750965

ABSTRACT

PURPOSE: Burkholderia cepacia complex (Bcc) is a diverse group of environmental bacteria associated with opportunistic infections. The identification of Bcc using conventional methods poses challenges. Bcc infections are difficult to treat due to intrinsic antibiotic resistance. The study aimed to investigate the species distribution and antimicrobial susceptibility of clinical Bcc isolates. METHODS: A total of 153 Bcc isolates obtained from clinical samples were analysed. Species identification was carried out using automated methods, including MALDI-TOF MS and VITEK2. Antimicrobial susceptibility testing was performed using the disc diffusion method. RESULTS: Burkholderia cenocepacia (70.5%) emerged as the most prevalent species, followed by Burkholderia contaminans (9.8%) and Burkholderia cepacia (7.2%). Ventilator-associated pneumonia (38.6%) was the most common infection, followed by sepsis (28.1%). Co-existence of Bcc with other pathogens in many cases suggested potential co-infection scenarios. Antimicrobial susceptibility revealed that ceftazidime, co-trimoxazole and meropenem were the most effective drugs, while levofloxacin proved to be the least effective. Moderate susceptibility was noted to minocycline, with 4.6% of isolates exhibiting multi-drug resistance. CONCLUSION: This study provides valuable insights into the prevalence, clinical associations, and antibiotic susceptibility of Bcc in India. It highlights the importance of Bcc as a nosocomial pathogen, especially in vulnerable patient populations. The findings contribute to understanding Bcc infections, their distribution, and emphasize the necessity for accurate identification methods in clinical settings.


Subject(s)
Anti-Bacterial Agents , Burkholderia Infections , Burkholderia cepacia complex , Microbial Sensitivity Tests , Tertiary Care Centers , Humans , India/epidemiology , Burkholderia Infections/microbiology , Burkholderia cepacia complex/drug effects , Burkholderia cepacia complex/isolation & purification , Burkholderia cepacia complex/classification , Anti-Bacterial Agents/pharmacology , Male , Female , Adult , Middle Aged , Young Adult , Adolescent , Aged , Child , Child, Preschool , Infant , Pneumonia, Ventilator-Associated/microbiology , Sepsis/microbiology , Aged, 80 and over , Coinfection/microbiology , Ceftazidime/pharmacology
16.
Emerg Infect Dis ; 30(6): 1249-1252, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38782141

ABSTRACT

Burkholderia semiarida was previously identified solely as a plant pathogen within the Burkholderia cepacia complex. We present a case in China involving recurrent pneumonia attributed to B. semiarida infection. Of note, the infection manifested in an immunocompetent patient with no associated primary diseases and endured for >3 years.


Subject(s)
Burkholderia Infections , Burkholderia , Recurrence , Humans , Burkholderia Infections/diagnosis , Burkholderia Infections/microbiology , Burkholderia Infections/drug therapy , China , Burkholderia/isolation & purification , Burkholderia/genetics , Male , Immunocompetence , Anti-Bacterial Agents/therapeutic use , Middle Aged , Pneumonia, Bacterial/microbiology , Pneumonia, Bacterial/diagnosis , Pneumonia, Bacterial/drug therapy
17.
AMA J Ethics ; 26(5): E367-372, 2024 May 01.
Article in English | MEDLINE | ID: mdl-38700520

ABSTRACT

Burkholderia cenocepacia (B cenocepacia) is a gram-negative bacteria associated with significant morbidity and mortality following lung transplantation. Most US transplant programs consider B cenocepacia colonization to be an absolute contraindication to transplantation. This article argues that, if clinicians have good clinical reasons to expect poor outcomes for patients with B cenocepacia, then offering transplantation anyway is an abrogation of clinicians' fiduciary duties. This article also discusses other fiduciary obligations transplant programs might have to patients with B cenocepacia, such as referring to another transplant center, considering novel treatment options, and investigating how the infection's virulence factors stratify that patient's risk for poor transplant outcomes.


Subject(s)
Burkholderia Infections , Lung Transplantation , Humans , Burkholderia cenocepacia , Drug Resistance, Bacterial , United States , Organ Transplantation/ethics , Anti-Bacterial Agents/therapeutic use , Health Services Accessibility
18.
Res Microbiol ; 175(5-6): 104202, 2024.
Article in English | MEDLINE | ID: mdl-38582389

ABSTRACT

The Burkholderia cepacia complex (Bcc) is a group of increasingly multi-drug resistant opportunistic bacteria. This resistance is driven through a combination of intrinsic factors and the carriage of a broad range of conjugative plasmids harbouring virulence determinants. Therefore, novel treatments are required to treat and prevent further spread of these virulence determinants. In the search for phages infective for clinical Bcc isolates, CSP1 phage, a PRD1-like phage was isolated. CSP1 phage was found to require pilus machinery commonly encoded on conjugative plasmids to facilitate infection of Gram-negative bacteria genera including Escherichia and Pseudomonas. Whole genome sequencing and characterisation of one of the clinical Burkholderia isolates revealed it to be Burkholderia contaminans. B. contaminans 5080 was found to contain a genome of over 8 Mbp encoding multiple intrinsic resistance factors, such as efflux pump systems, but more interestingly, carried three novel plasmids encoding multiple putative virulence factors for increased host fitness, including antimicrobial resistance. Even though PRD1-like phages are broad host range, their use in novel antimicrobial treatments shouldn't be dismissed, as the dissemination potential of conjugative plasmids is extensive. Continued survey of clinical bacterial strains is also key to understanding the spread of antimicrobial resistance determinants and plasmid evolution.


Subject(s)
Bacteriophages , Burkholderia cepacia complex , Plasmids , Plasmids/genetics , Burkholderia cepacia complex/virology , Burkholderia cepacia complex/genetics , Burkholderia cepacia complex/isolation & purification , Bacteriophages/genetics , Bacteriophages/isolation & purification , Bacteriophages/classification , Host Specificity , Whole Genome Sequencing , Conjugation, Genetic , Virulence Factors/genetics , Burkholderia Infections/microbiology , Humans , Genome, Viral , Genome, Bacterial , Burkholderia/genetics , Burkholderia/virology
19.
Emerg Infect Dis ; 30(5): 1055-1057, 2024 May.
Article in English | MEDLINE | ID: mdl-38666739

ABSTRACT

We report a clinical isolate of Burkholderia thailandensis 2022DZh obtained from a patient with an infected wound in southwest China. Genomic analysis indicates that this isolate clusters with B. thailandensis BPM, a human isolate from Chongqing, China. We recommend enhancing monitoring and surveillance for B. thailandensis infection in both humans and livestock.


Subject(s)
Burkholderia Infections , Burkholderia , Phylogeny , Wound Infection , Humans , Male , Burkholderia/genetics , Burkholderia/isolation & purification , Burkholderia/classification , Burkholderia Infections/microbiology , Burkholderia Infections/diagnosis , China/epidemiology , Genome, Bacterial , Wound Infection/microbiology , Middle Aged
20.
Arch Microbiol ; 206(4): 159, 2024 Mar 14.
Article in English | MEDLINE | ID: mdl-38483625

ABSTRACT

Burkholderia cepacia complex (BCC) is a Gram-negative, non-spore-forming bacterium with more than 20 opportunistic pathogenic species, most commonly found in soil and water. Due to their rapid mutation rates, these organisms are adaptable and possess high genomic plasticity. BCC can cause life-threatening infections in immunocompromised individuals, such as those with cystic fibrosis, chronic granulomatous disease, and neonates. BCC contamination is a significant concern in pharmaceutical manufacturing, frequently causing non-sterile product recalls. BCC has been found in purified water, cosmetics, household items, and even ultrasound gel used in veterinary practices. Pharmaceuticals, personal care products, and cleaning solutions have been implicated in numerous outbreaks worldwide, highlighting the risks associated with intrinsic manufacturing site contamination. Regulatory compliance, product safety, and human health protection depend on testing for BCC in pharmaceutical manufacturing. Identification challenges exist, with BCC often misidentified as other bacteria like non-lactose fermenting Escherichia coli or Pseudomonas spp., particularly in developing countries where reporting BCC in pharmaceuticals remains limited. This review comprehensively aims to address the organisms causing BCC contamination, genetic diversity, identification challenges, regulatory requirements, and mitigation strategies. Recommendations are proposed to aid pharmaceutical chemists in managing BCC-associated risks and implementing prevention strategies within manufacturing processes.


Subject(s)
Burkholderia Infections , Burkholderia cepacia complex , Cystic Fibrosis , Infant, Newborn , Humans , Burkholderia cepacia complex/genetics , Burkholderia Infections/prevention & control , Burkholderia Infections/complications , Burkholderia Infections/epidemiology , Cystic Fibrosis/microbiology , Water , Pharmaceutical Preparations
SELECTION OF CITATIONS
SEARCH DETAIL